Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing treatments for neurological disorders caused by imbalances between excitatory and inhibitory neural activity. The company uses two main technology platforms—one for small molecule therapies and another for antisense oligonucleotide drugs—to create oral and injectable treatments targeting conditions like epilepsy and essential tremor. Its pipeline includes candidates in late-stage development, such as ulixacaltamide for essential tremor and relutrigine for genetic epilepsy types, alongside earlier-stage programs addressing rare genetic neurological disorders.

entry readiness 36 · WEAK SETUP · exit proximity 0

Value area 294.18–361.91 · 72% of 120d volume overhead · heavy supply